Could an old transplant drug help beat brain cancer?

NCT ID NCT07605364

Not yet recruiting Disease control Sponsor: Alliance for Clinical Trials in Oncology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests whether adding mycophenolate mofetil, a drug usually used in organ transplants, to standard radiation and chemotherapy can help people with advanced glioblastoma live longer. About 422 participants will receive either the standard treatment or standard treatment plus mycophenolate mofetil. The goal is to see if the combination slows tumor growth and improves survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mycophenolate mofetil
What this could lead to: If it works, this could extend survival for people with advanced glioblastoma by making standard treatments more effective.
What could go wrong: This is an early phase II/III trial, so results are uncertain. Adding mycophenolate mofetil may increase side effects without improving outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates